Chronic Myeloproliferative Disorders Clinical Trial
Official title:
Phase II Study of the Combination of Low-Dose Thalidomide, Prednisone, and Oral Cyclophosphamide ("TPC") in the Therapy of Myelofibrosis With Myeloid Metaplasia (MMM)
RATIONALE: Giving thalidomide together with prednisone and cyclophosphamide may lessen
symptoms caused by myelofibrosis and myeloid metaplasia.
PURPOSE: This phase II trial is studying the side effects and how well giving thalidomide
together with prednisone and cyclophosphamide works in treating patients with myelofibrosis
and myeloid metaplasia.
OBJECTIVES:
Primary
- Determine the benefit of thalidomide, prednisone, and cyclophosphamide in alleviating
disease-associated anemia, thrombocytopenia, and/or splenomegaly in patients with
myelofibrosis with myeloid metaplasia (MMM).
- Determine the benefit of this regimen in palliating four hypercatabolic constitutional
symptoms (i.e., weight loss, fatigue, drenching night sweats, and unexplained fevers)
in these patients.
- Determine the toxicity profile of this regimen in these patients.
Secondary
- Determine the effect of this regimen on leukocyte count.
- Determine the effect of this regimen on bone marrow histology, including microvessel
density and reticulin fibrosis.
- Determine the effect of this regimen on intramedullary and urinary markers of
angiogenesis.
- Determine the effect of this regimen on circulating myeloid progenitor cells by
quantifying CD34+ cells.
OUTLINE: Patients receive oral thalidomide, oral prednisone, and oral cyclophosphamide (TPC)
once daily on days 1-28. Treatment repeats every 28 days for 3 courses. After 3 courses (3
months) of treatment, patients who respond to TPC therapy may receive oral thalidomide alone
once daily for up to 3 months in the absence of disease progression or unacceptable
toxicity.
Patients undergo bone marrow aspirate and biopsy prior to study entry, 6 months after
starting therapy, and then every 6 months for up to 3 years. Samples are analyzed by
microvessel density/angiogenesis studies (i.e., CD34 immunohistochemical and vascular
endothelium-specific staining) to determine the effect of therapy on markers of bone marrow
angiogenesis.
After completion of study therapy, patients are followed every 6 months for up to 3 years.
PROJECTED ACCRUAL: A total of 22 patients will be accrued for this study.
;
Masking: Open Label, Primary Purpose: Treatment
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT01164163 -
INCB18424 in Treating Young Patients With Relapsed or Refractory Solid Tumor, Leukemia, or Myeloproliferative Disease
|
Phase 1 | |
Recruiting |
NCT01137825 -
Registry of Older Patients With Cancer
|
||
Suspended |
NCT00935090 -
3'-Deoxy-3'-[18F] Fluorothymidine PET Imaging in Patients With Cancer
|
N/A | |
Withdrawn |
NCT00816413 -
Donor Stem Cell Transplant, Pentostatin, and Total-Body Irradiation in Treating Patients With Hematological Cancer
|
Phase 1/Phase 2 | |
Completed |
NCT00437086 -
Bortezomib in Treating Patients With Advanced Myeloproliferative Disorders
|
Phase 0 | |
Completed |
NCT00951626 -
A Standardized Nursing Intervention Protocol for HCT Patients
|
N/A | |
Terminated |
NCT00005641 -
Removal of T Cells to Prevent Graft-Versus-Host Disease in Patients Undergoing Bone Marrow Transplantation
|
Phase 2 | |
Active, not recruiting |
NCT00755040 -
Cyclosporine Eye Drops in Preventing Graft-Versus-Host Disease of the Eye in Patients Who Have Undergone Donor Stem Cell Transplant for Hematologic Cancer or Bone Marrow Failure Disorder
|
Phase 3 | |
Completed |
NCT00719563 -
American Ginseng in Treating Patients With Fatigue Caused by Cancer
|
Phase 3 | |
Terminated |
NCT00899951 -
Studying Fentanyl in Patients With Cancer
|
N/A | |
Active, not recruiting |
NCT00448357 -
Fludarabine and PK-Directed Busulfan With or Without ATG Followed By Donor Peripheral Stem Cell Transplant in Treating Patients With Hematologic Cancer or Other Diseases
|
Phase 1/Phase 2 | |
Completed |
NCT00274820 -
Arsenic Trioxide, Ascorbic Acid, Dexamethasone, and Thalidomide in Myelofibrosis/Myeloproliferative Disorder
|
Phase 2 | |
Completed |
NCT00134004 -
Fludarabine, Cyclophosphamide, and Total-Body Irradiation in Treating Patients Who Are Undergoing a Donor Bone Marrow Transplant for Hematologic Cancer
|
Phase 2 | |
Completed |
NCT00293384 -
Aprepitant, Granisetron, & Dexamethasone in Preventing Nausea & Vomiting in Pts. Receiving Cyclophosphamide Before a Stem Cell Transplant
|
N/A | |
Completed |
NCT00054340 -
Combination Chemotherapy and Antithymocyte Globulin in Reducing Graft-Versus-Host Disease in Patients Undergoing Donor Stem Cell Transplantation For Myelodysplastic Syndrome or Myeloproliferative Disorder
|
Phase 1/Phase 2 | |
Completed |
NCT00006348 -
Ondansetron in Treating Patients With Advanced Cancer and Chronic Nausea and Vomiting Not Caused by Cancer Treatment
|
Phase 3 | |
Completed |
NCT00004904 -
Stem Cell Transplantation in Treating Patients With Hematologic Cancer
|
Phase 1 | |
Completed |
NCT00004181 -
Bone Marrow Transplantation in Treating Patients With Multiple Myeloma, Chronic Phase Chronic Myelogenous Leukemia, or Agnogenic Myeloid Metaplasia
|
Phase 2 | |
Completed |
NCT00005804 -
Bone Marrow Transplantation in Treating Patients With Hematologic Cancer
|
Phase 2 | |
Terminated |
NCT00290628 -
Donor Umbilical Cord Blood Transplant in Treating Patients With Hematologic Cancer
|
N/A |